Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

doi:10.1126/scitranslmed.3002003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Science translational medicine - 23 Mar 2011

Sequist Lecia V, Waltman Belinda A, Dias-Santagata Dora, Digumarthy Subba, Turke Alexa B, Fidias Panos, Bergethon Kristin, Shaw Alice T, Gettinger Scott, Cosper Arjola K, Akhavanfard Sara, Heist Rebecca S, Temel Jennifer, Christensen James G, Wain John C, Lynch Thomas J, Vernovsky Kathy, Mark Eugene J, Lanuti Michael, Iafrate A John, Mino-Kenudson Mari, Engelman Jeffrey A

Abstract excerpt

Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate mechanisms of acquired drug resistance, we performed systematic genetic and histological analyses of tumor biopsies from 37 patients with drug-resistant non-small cell lung cancers (NSCLCs) carrying EGFR mutations. All drug-resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 21430269
DOI: 10.1126/scitranslmed.3002003
PMCID: PMC3132801

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.PMID 21430269Read ↗

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Semantic proximity Read ↗

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.Semantic proximity Read ↗

Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic SequencingSemantic proximity Read ↗

Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Overcoming therapy resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.Semantic proximity Read ↗

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.Semantic proximity Read ↗

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.Semantic proximity Read ↗

Rare transformation from lung adenocarcinoma to sarcomatoid carcinoma mediates resistance to inhibitors targeting different driver oncogenesSemantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Semantic proximity Read ↗

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.